Proteasome inhibitor-based therapy for treatment of newly diagnosed multiple myeloma
作者： Andrae Vandross
DOI: 10.1053/J.SEMINONCOL.2018.01.002
关键词:
摘要: Multiple myeloma is a hematologic malignancy that unable to be cured and has significant impact throughout the world. Front line treatment shifted but ultimately landed on bortezomib-based combination therapy. Carfilzomib next-generation proteasome inhibitor shown improve both progression-free overall survival in relapsed refractory multiple with lenalidomide dexamethasone (KRd). Given favorable response rates seen phase II trials treating newly diagnosed myeloma, this listed as viable option for upfront treatment. This systematic review compares pharmacologic properties, clinical efficacy, toxicities of carfilzomib- regimens.
elsevier.com
sci-hub.se 参考文章(19)
Neha Korde, Mark Roschewski, Adriana Zingone, Mary Kwok, Elisabet E. Manasanch, Manisha Bhutani, Nishant Tageja, Dickran Kazandjian, Sham Mailankody, Peter Wu, Candis Morrison, Rene Costello, Yong Zhang, Debra Burton, Marcia Mulquin, Diamond Zuchlinski, Liz Lamping, Ashley Carpenter, Yvonne Wall, George Carter, Schuyler C. Cunningham, Verena Gounden, Tristan M. Sissung, Cody Peer, Irina Maric, Katherine R. Calvo, Raul Braylan, Constance Yuan, Maryalice Stetler-Stevenson, Diane C. Arthur, Katherine A. Kong, Li Weng, Malek Faham, Liza Lindenberg, Karen Kurdziel, Peter Choyke, Seth M. Steinberg, William Figg, Ola Landgren, Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma. JAMA Oncology. ,vol. 1, pp. 746- 754 ,(2015) , 10.1001/JAMAONCOL.2015.2010
Paul G. Richardson, Edie Weller, Sagar Lonial, Andrzej J. Jakubowiak, Sundar Jagannath, Noopur S. Raje, David E. Avigan, Wanling Xie, Irene M. Ghobrial, Robert L. Schlossman, Amitabha Mazumder, Nikhil C. Munshi, David H. Vesole, Robin Joyce, Jonathan L. Kaufman, Deborah Doss, Diane L. Warren, Laura E. Lunde, Sarah Kaster, Carol DeLaney, Teru Hideshima, Constantine S. Mitsiades, Robert Knight, Dixie-Lee Esseltine, Kenneth C. Anderson, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. ,vol. 116, pp. 679- 686 ,(2010) , 10.1182/BLOOD-2010-02-268862
A Keith Stewart, S Vincent Rajkumar, Meletios A Dimopoulos, Tamás Masszi, Ivan Špička, Albert Oriol, Roman Hájek, Laura Rosiñol, David S Siegel, Georgi G Mihaylov, Vesselina Goranova-Marinova, Péter Rajnics, Aleksandr Suvorov, Ruben Niesvizky, Andrzej J Jakubowiak, Jesus F San-Miguel, Heinz Ludwig, Michael Wang, Vladimír Maisnar, Jiri Minarik, William I Bensinger, Maria-Victoria Mateos, Dina Ben-Yehuda, Vishal Kukreti, Naseem Zojwalla, Margaret E Tonda, Xinqun Yang, Biao Xing, Philippe Moreau, Antonio Palumbo, None, Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma The New England Journal of Medicine. ,vol. 372, pp. 142- 152 ,(2015) , 10.1056/NEJMOA1411321
Shaji Kumar, Ian Flinn, Paul G. Richardson, Parameswaran Hari, Natalie Callander, Stephen J. Noga, A. Keith Stewart, Francesco Turturro, Robert Rifkin, Jeffrey Wolf, Jose Estevam, George Mulligan, Hongliang Shi, Iain J. Webb, S. Vincent Rajkumar, Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma Blood. ,vol. 119, pp. 4375- 4382 ,(2012) , 10.1182/BLOOD-2011-11-395749
Sundar Jagannath, Brian G. M. Durie, Jeffrey Wolf, Elber Camacho, David Irwin, Jose Lutzky, Marti McKinley, Eli Gabayan, Amitabha Mazumder, David Schenkein, John Crowley, Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. British Journal of Haematology. ,vol. 129, pp. 776- 783 ,(2005) , 10.1111/J.1365-2141.2005.05540.X
Andrzej J. Jakubowiak, Dominik Dytfeld, Kent A. Griffith, Daniel Lebovic, David H. Vesole, Sundar Jagannath, Ammar Al-Zoubi, Tara Anderson, Brian Nordgren, Kristen Detweiler-Short, Keith Stockerl-Goldstein, Asra Ahmed, Terri Jobkar, Diane E. Durecki, Kathryn McDonnell, Melissa Mietzel, Daniel Couriel, Mark Kaminski, Ravi Vij, A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma Blood. ,vol. 120, pp. 1801- 1809 ,(2012) , 10.1182/BLOOD-2012-04-422683
Jesús F San Miguel, Rudolf Schlag, Nuriet K Khuageva, Meletios A Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Maria T Petrucci, Antonio Palumbo, Olga S Samoilova, Anna Dmoszynska, Kudrat M Abdulkadyrov, Rik Schots, Bin Jiang, Maria-Victoria Mateos, Kenneth C Anderson, Dixie L Esseltine, Kevin Liu, Andrew Cakana, Helgi Van De Velde, Paul G Richardson, None, Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. The New England Journal of Medicine. ,vol. 359, pp. 906- 917 ,(2008) , 10.1056/NEJMOA0801479
Maria-Victoria Mateos, Paul G. Richardson, Rudolf Schlag, Nuriet K. Khuageva, Meletios A. Dimopoulos, Ofer Shpilberg, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Antonio Palumbo, Olga S. Samoilova, Anna Dmoszynska, Kudrat M. Abdulkadyrov, Rik Schots, Bin Jiang, Dixie L. Esseltine, Kevin Liu, Andrew Cakana, Helgi van de Velde, Jesús F. San Miguel, Bortezomib Plus Melphalan and Prednisone Compared With Melphalan and Prednisone in Previously Untreated Multiple Myeloma: Updated Follow-Up and Impact of Subsequent Therapy in the Phase III VISTA Trial Journal of Clinical Oncology. ,vol. 28, pp. 2259- 2266 ,(2010) , 10.1200/JCO.2009.26.0638
P. Moreau, H. Pylypenko, S. Grosicki, I. Karamanesht, X. Leleu, G. Rekhtman, Z. Masliak, P. Robak, D.-L. Esseltine, H. Feng, W. Deraedt, H. van de Velde, B. Arnulf, Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study Haematologica. ,vol. 100, ,(2015) , 10.3324/HAEMATOL.2014.118182
Murielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, Cyrille Hulin, Xavier Leleu, Lotfi Benboubker, Gérald Marit, Philippe Moreau, Brigitte Pegourie, Denis Caillot, Christophe Fruchart, Anne-Marie Stoppa, Catherine Gentil, Soraya Wuilleme, Anne Huynh, Benjamin Hebraud, Jill Corre, Marie-Lorraine Chretien, Thierry Facon, Hervé Avet-Loiseau, Michel Attal, Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du Myélome Journal of Clinical Oncology. ,vol. 32, pp. 2712- 2717 ,(2014) , 10.1200/JCO.2013.54.8164